Oxytocin

What is oxytocin?

Oxytocin is a peptide hormone of the posterior lobe of the pituitary. According to the SmPC (Turkish KÜB), it increases the frequency and strength of uterine contractions during childbirth, speeds the uterus’s return to its size after birth, and contracts the myoepithelial cells in the mammary gland, facilitating milk letdown. Oxytocin receptors in the uterine muscle increase toward the end of pregnancy; stimulation of the receptor triggers calcium release inside the cell and leads to contraction. ^[2]

The oxytocin used as a drug is synthetic and does not contain vasopressin, the other posterior lobe hormone of the pituitary; for this reason it does not raise blood pressure at recommended doses. However, even in pure form it has a weak, vasopressin-like antidiuretic effect. Its half-life in the blood is between 3 and 20 minutes. According to laboratory studies, prolonged exposure can cause desensitization of oxytocin receptors. ^[2]

In popular culture it is called the “love hormone” or the “bonding hormone”, and as a nasal spray it has been tried for social behavior, autism, trust and anxiety. What these trials did and did not show in humans is covered separately below.

What is it used for in and after childbirth?

The indications in the SmPC of a licensed oxytocin product in Türkiye are as follows: ^[2]

• Before birth: Induction of labor for medical reasons (for example post-term pregnancy, premature rupture of membranes, pregnancy-related high blood pressure); stimulation of labor when contractions are weak; as an adjunct in the treatment of incomplete or delayed miscarriage in early pregnancy.
• After birth: After the baby is delivered during cesarean section; prevention and treatment of postpartum uterine atony and bleeding.

The evidence on preventing postpartum hemorrhage is summarized in the 2019 Cochrane review. The review includes 24 studies; 23 studies provide data from 10,018 women. In women giving birth vaginally, compared with placebo or no uterotonic drug, oxytocin given prophylactically in the third stage of labor: ^[3]

• may reduce the risk of bleeding of 500 mL or more (RR 0.51, 95% CI 0.37–0.72; 6 studies, 4,162 women; low-quality evidence),
• may reduce the risk of bleeding of 1,000 mL or more (RR 0.59, 95% CI 0.42–0.83; 5 studies, 4,123 women; low-quality evidence),
• probably reduces the need for additional uterotonic drugs (RR 0.54, 95% CI 0.36–0.80; 4 studies, 3,135 women; moderate-quality evidence),
• may make no difference in the need for blood transfusion (RR 0.88, 95% CI 0.44–1.78; 3 studies, 3,081 women; low-quality evidence).

When compared with ergot alkaloids, it is uncertain whether oxytocin reduces bleeding (very low-quality evidence); the risk of vomiting is probably lower with oxytocin, and the risk of the placenta taking longer than 30 minutes to separate is probably higher. ^[3]

Risks of use in childbirth

Oxytocin is a drug given in the delivery room under the supervision of a physician and midwife, by infusion pump. According to the SmPC, because the sensitivity of the uterus varies greatly from person to person, uterine spasm can be seen even at doses considered low; overdose can lead to overstimulation of the uterus, distress and oxygen deprivation in the baby, and uterine rupture. When given with large amounts of fluid for a long time, water intoxication with low sodium has been reported in the mother and newborn. Anaphylaxis has been reported after oxytocin in women with latex allergy; caution is required in severe renal failure because of the risk of fluid retention and accumulation. Mechanical obstruction in childbirth, fetal distress and situations in which vaginal delivery is not appropriate are contraindications. ^[2]

Does oxytocin nasal spray work in autism?

Experimental studies and small clinical trials suggested that oxytocin nasal spray might reduce social difficulties in autism, and oxytocin has been given in clinical practice to many children with autism. ^[4] The large and long randomized studies done afterward did not confirm this hope:

There is also data that conflicts with this table: a 2021 multilevel meta-analysis combined 28 studies with 726 patients and concluded that oxytocin has a beneficial effect on social functioning. However, this meta-analysis included single-arm, non-randomized and uncontrolled studies as well as randomized studies; strong evidence was not found for non-social symptoms. ^[7] The authors of the Sikich study, the largest and longest RCT, report that there was no significant difference between groups in social or cognitive functioning over 24 weeks of treatment. ^[4]

What is known about trust, bonding and anxiety?

The source of oxytocin’s “trust hormone” reputation is a study published in 2005 reporting that investors who received oxytocin nasally entrusted more money to strangers in a trust game. The results of later studies were inconsistent. A preregistered, double-blind, placebo-controlled replication study published in 2020 applied the conditions of the first study exactly (minimal social contact between participants) and had a statistical power above 95%. In this condition, no effect of oxytocin on trust behavior was found. In exploratory analyses done afterward, an effect was seen in people with low trusting tendency in the condition without social contact; the authors note that this needs separate confirmation. ^[8]

In anxiety and depression, a 2019 systematic review examined 15 RCTs: 7 studies were on social anxiety disorder, 1 on spider phobia, 3 on major depression and 4 on postpartum depression, and most gave a single dose. No significant effect was found on core symptoms. In one of five crossover studies with brain imaging, amygdala hyperreactivity decreased in anxious people; the review describes the evidence as “inconclusive” and writes that larger, longer studies are needed. ^[9]

Does oxytocin given through the nose reach the brain?

The answer to this question is disputed. According to the 2016 critical review by the Edinburgh-based physiologists Leng and Ludwig, very little of the large amounts given through the nose reaches the cerebrospinal fluid; in contrast, the level in the blood rises above physiological limits and the possibility of effects on targets outside the brain, such as the digestive tract, heart and reproductive organs, arises. The authors stress that a significant part of blood oxytocin measurements were made with methods whose reliability has been questioned, and that experiments should be preregistered and tested with proper dose-response studies. ^[10]

Are nasal sprays safe?

The most comprehensive safety data on short-term use in research settings come from a 2011 review. In 38 RCTs done between 1990 and 2010, 1,529 participants (79% male) were examined; side effects did not differ between the oxytocin and placebo groups, and participants could not correctly guess which they had received. The review found no association with adverse outcomes in short-term use under controlled research conditions; however, it identified three case reports related to misuse and long-term use. The authors note that research is needed for longer use, children, women and vulnerable groups. ^[11]

These safety data are for research products of known purity and short-term use. Properties such as the antidiuretic effect of oxytocin and receptor desensitization with prolonged exposure are described in the SmPC. ^[2]

General peptide side effects are in a separate guide: Peptide side effects

FDA, WADA and Türkiye: what is the legal status?

US

The once-approved oxytocin nasal spray in the US (NDA 012285) appears in the Drugs@FDA record as “Discontinued”. ^[12]

Sport (WADA)

In the WADA list valid from January 1, 2026, oxytocin is not named. Class S0 of the list covers only substances not approved by any official health authority for therapeutic use in humans; oxytocin is a licensed drug. ^[13]

Türkiye

The TİTCK (Turkish Medicines and Medical Devices Agency) Licensed Human Medicinal Products List dated October 16, 2026 contains four products with oxytocin as an active substance; all are injectable solutions. There is no nasal spray containing oxytocin on the list. Injectable products containing carbetocin, an analog of oxytocin, are also on the list. ^[1]

For this reason, oxytocin products offered in Türkiye as nasal sprays, “for research purposes” or as supplements are unlicensed. Article 19 of Law No. 1262 (İspençiyari ve Tıbbi Müstahzarlar Kanunu) punishes those who manufacture unlicensed preparations and those who knowingly sell, offer for sale or have sold such preparations with imprisonment from one to five years; the same penalty is prescribed for those who sell or advertise a product that is not a preparation with the claim that it treats diseases. Importing preparations made abroad without a license for commercial purposes counts as smuggling. ^[14]

The meaning of the “for research purposes” label: What does research peptide mean? · General framework: Are peptides legal?

Evidence table: claim, population and limits

Limits of this guide

This page summarizes the official product information on oxytocin, Cochrane and other reviews, large randomized studies and official agency records. It gives no dose, cycle, preparation, administration technique or product-sourcing information. The use of oxytocin in childbirth is solely the decision of the delivery team; autism, anxiety and depression are conditions that must be evaluated by a physician.